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Abstract
Chronic kidney disease (CKD) is an important public health problem with a genetic component. We performed genome-
wide association studies in up to 130,600 European ancestry participants overall, and stratified for key CKD risk factors. We
uncovered 6 new loci in association with estimated glomerular filtration rate (eGFR), the primary clinical measure of CKD, in
or near MPPED2, DDX1, SLC47A1, CDK12, CASP9, and INO80. Morpholino knockdown of mpped2 and casp9 in zebrafish
embryos revealed podocyte and tubular abnormalities with altered dextran clearance, suggesting a role for these genes in
renal function. By providing new insights into genes that regulate renal function, these results could further our
understanding of the pathogenesis of CKD.
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Introduction
Chronic kidney disease (CKD) affects nearly 10% of the global
population [1,2], and its prevalence continues to increase [3].
Reduced estimated glomerular filtration rate (eGFR), the primary
measure used to define CKD (eGFR,60 ml/min/1.73 m2) [4], is
associated with an increased risk of cardiovascular morbidity and
mortality [5], acute kidney injury [6], and end stage renal disease
(ESRD) [6,7].
Using genome-wide association studies (GWAS) in predomi-
nantly population-based cohorts, we and others have previously
identified more than 20 genetic loci associated with eGFR and
CKD [8–11]. Although most of these genetic effects seem largely
robust across strata of diabetes or hypertension status [9], evidence
suggests that some of the loci such as the UMOD locus may have
heterogeneous effects across these strata [11]. We thus hypothe-
sized that GWAS in study populations stratified by four key CKD
risk factors - age, sex, diabetes or hypertension status - may permit
the identification of novel eGFR and CKD loci. We carried this
out by extending our previous work [9] to a larger discovery
sample of 74,354 individuals with independent replication in
additional 56,246 individuals, resulting in a total of 130,600
individuals of European ancestry. To assess for potential
heterogeneity, we performed separate genome-wide association
analyses across strata of CKD risk factors, as well as in a more
extreme CKD phenotype.
Results
Meta-analyses of GWAS on the 22 autosomes were performed
for: 1) eGFR based on serum creatinine (eGFRcrea) and CKD
(6,271 cases) in the overall sample, 2) eGFRcrea and CKD
stratified by the four risk factors, and 3) CKD45, a more severe
CKD phenotype defined as eGFRcrea ,45 ml/min/1.73 m2 in
GWAS Reveals New Loci for Kidney Function
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the overall sample (2,181 cases). For the stratified analyses, in
addition to identifying loci that were significant within each
stratum, we performed a genome-wide comparison of the effect
estimates between strata of the four risk factors. A complete
overview of the analysis workflow is given in Figure S1. All studies
participating in the stage 1 discovery and stage 2 replication
phases are listed in Tables S1 and S2. The characteristics of all
stage 1 discovery samples by study are reported in Table S3, and
information on study design and genotyping are reported in
Table S4. Results of the eGFRcrea analyses are summarized in
the Manhattan and quantile-quantile plots reported in Figures S2
and S3. A total of 21 SNPs from the discovery stage were carried
forward for replication in an independent set of 56,246
individuals (Tables S5 and S6). These SNPs were selected for
replication for the following (Figure S1): 5 reached genome-wide
significance in either eGFRcrea overall or stratified analyses, 1
based on a test of direction-consistency of SNP-eGFR associa-
tions across the discovery cohorts for eGFRcrea overall, 4
demonstrated a P value#1026 and high between-study homoge-
neity (I2,25%) in the CKD45 analysis (Table S7), and 11
demonstrated between-strata P value#561025 along with a P
value#561025 for association with eGFRcrea in at least one of
the two strata (Table S8).
While none of the loci identified for CKD45 or the test for
between-strata difference analyses replicated, all 6 loci identified
from the eGFRcrea overall analysis, stratified analyses, and the
direction test did (Table 1). These 6 loci were identified and
replicated in the overall analysis (rs3925584, located upstream of the
MPPED2 gene; rs6431731 near theDDX1 gene), in the diabetes-free
sub-group (rs2453580 in an intron of the SLC47A1 gene), in the
younger age stratum (rs11078903 in an intron of the CDK12 gene;
rs12124078 located near the CASP9 gene), and the direction test
(rs2928148, located in the INO80 gene, see Methods for details). In
the combined meta-analysis of all 45 studies used in the discovery
and replication stages, all six SNPs met the genome-wide
significance threshold of 561028, with individual P values ranging
from 4.361028 to 8.4610218 (Table 1). The imputation quality of
these SNPs is reported in Table S9, and Figure S4 shows the
regional association plots for each of the 6 loci. We also confirmed
all previously identified renal function loci in the current data (Table
S10). Brief descriptions of the genes included within the 6 new loci
uncovered can be found in Table S11. Forest plots for the
associations between the index SNP at each of the 6 novel loci and
eGFR across all discovery studies and all strata are presented in
Figures S5 and S6. Most of the 6 new loci had similar associations
across strata of CKD risk factors except for the CDK12 locus, which
revealed stronger association in the younger (#65 years of age) as
compared to the older age group (.65 years of age).
We further examined our findings in 8,110 African ancestry
participants from the CARe consortium [12] (Table 2). Not
surprisingly, given linkage disequilibrium (LD) differences between
Europeans and African Americans, none of the 6 lead SNPs
uncovered in CKDGen achieved significance in the African
American samples. Next, we interrogated the 250 kb flanking
regions from the lead SNP at each locus, and showed that 4 of the
6 regions (MPPED2, DDX1, SLC47A1, and CDK12) harbored
SNPs that achieved statistical significance after correcting for
multiple comparisons based on the genetic structure of each region
(see Methods for details). Figure 1 presents the regional association
plots for MPPED2, and Figure S7 presents the plots of the
remaining loci in the African American sample. Imputation scores
for the lead SNPs can be found in Table S12. We observed that
rs12278026, upstream ofMPPED2, was associated with eGFRcrea
in African Americans (P value = 561025, threshold for statistical
significance: P value = 0.001). While rs12278026 is monomorphic
in the CEU population in HapMap, rs3925584 and rs12278026
have a D9 of 1 (r2 = 0.005) in the YRI population, suggesting that
these SNPs may have arisen from the same ancestral haplotype.
We also performed eQTL analyses of our 6 newly identified loci
using known databases and a newly created renal eSNP database
(see Methods) and found that rs12124078 was associated with cis
expression of the nearby CASP9 gene in myocytes, which encodes
caspase-9, the third apoptotic activation factor involved in the
activation of cell apoptosis, necrosis and inflammation (P value for
the monocyte eSNP of interest = 3.7610213). In the kidney,
caspase-9 may play an important role in the medulla response to
hyperosmotic stress [13] and in cadmium-induced toxicity [14].
The other 5 SNPs were not associated with any investigated eQTL.
Additional eQTL analyses of 81 kidney biopsies (Table S13) did not
reveal further evidence of association with eQTLs (Table S14).
Of the 6 novel loci identified, 2 (MPPED2 and DDX1) were in
regions containing only a single gene, and 1 (CASP9) had its
expression associated with the locus lead SNP. Thus, to determine
the potential involvement of these three genes during zebrafish
kidney development, we independently assessed the expression of
4 well-characterized renal markers following morpholino knock-
down: pax2a (global kidney) [15], nephrin (podocyte) [16], slc20a1a
(proximal tubule) [17], and slc12a3 (distal tubule) [17]. While we
observed no abnormalities in ddx1 morphants (Figure S8), mpped2
and casp9 knockdown resulted in expanded pax2a expression in the
glomerular region in 90% and 75% of morphant embryos,
respectively, compared to 0% in controls (P value,0.0001 for both
genes; Figure 2A versus 2F and 2K; 2B versus 2G and 2L; and 2P).
Significant differences were also observed in expression of the
podocyte marker nephrin (Figure 2C versus 2H and 2M; 80% and
74% abnormalities for mpped2 and casp9, respectively, versus 0% in
controls, P value,0.0001 for both genes). For mpped2, no
differences were observed in expression of the proximal or distal
tubular markers slc20a1a and slc12a3 (P value = 1.0; Figure 2D
versus 2I and 2E versus 2J). Casp9 morphants and controls showed
no differences in proximal tubular marker expression (Figure 2D
versus 2N), but abnormalities were observed in distal tubular
marker expression in casp9 knockdown embryos (30% versus 0%;
Figure 2E versus 2O; P value = 0.0064).
Author Summary
Chronic kidney disease (CKD) is an important public health
problem with a hereditary component. We performed a
new genome-wide association study in up to 130,600
European ancestry individuals to identify genes that may
influence kidney function, specifically genes that may
influence kidney function differently depending on sex,
age, hypertension, and diabetes status of individuals. We
uncovered 6 new loci associated with estimated glomer-
ular filtration rate (eGFR), the primary measure of renal
function, in or near MPPED2, DDX1, SLC47A1, CDK12, CASP9,
and INO80. CDK12 effect was stronger in younger and
absent in older individuals. MPPED2, DDX1, SLC47A1, and
CDK12 loci were associated with eGFR in African ancestry
samples as well, highlighting the cross-ethnicity validity of
our findings. Using the zebrafish model, we performed
morpholino knockdown of mpped2 and casp9 in zebrafish
embryos and revealed podocyte and tubular abnormalities
with altered dextran clearance, suggesting a role for these
genes in renal function. These results further our
understanding of the pathogenesis of CKD and provide
insights into potential novel mechanisms of disease.
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Casp9 morphants displayed diminished clearance of 70,000 MW
fluorescent dextran 48 hours after injection into the sinus venosus
compared to controls, revealing significant functional consequences
of casp9 knockdown (Figure 2Q–2V). No clearance abnormalities
were observed in mpped2 morphants. The occurrence of abdominal
edema is a non-specific finding that is frequently observed in
zebrafish embryos with kidney defects. We examined the occur-
rence of edema in mpped2 and casp9 knockdown embryos at 4 and 6
days post fertilization (dpf), both in the absence and presence of
dextran, and observed a significant increase in edema prevalence in
casp9 with (P value,0.0001) and without (P value= 0.0234) dextran
challenge but not in mpped2 morphants (Figure 2W).
In order to further demonstrate differences in kidney function in
response to knockdown of mpped2 and casp9, we injected the
nephrotoxin gentamicin which predictably causes edema in a subset
of embryos. Casp9 morphants were more susceptible to developing
edema compared to both controls and mpped2 morphants
(Figure 2X). In addition, edema developed earlier and was more
severe, encompassing a greater area of the entire embryo (Figure
S9). Together, these findings suggest that casp9 and mpped2
knockdowns result in altered kidney gene expression and function.
Specifically, abnormal expression of pax2a and nephrin in casp9
morphants in addition to dextran retention and edema formation
suggest loss of casp9 impacts glomerular development and function.
The lead SNP at the MPPED2 locus is located approximately
100 kb upstream of the gene metallophosphoesterase domain
containing 2 (MPPED2), which is highly evolutionary conserved
and encodes a protein with metallophosphoesterase activity [18].
It has been recognized for a role in brain development and
tumorigenesis [19] but thus far not for kidney function.
To determine whether the association at our newly identified
eGFRcrea loci was primarily due to creatinine metabolism or renal
function, we compared the relative associations between eGFRcrea
and eGFR estimated using cystatin C (eGFRcys) (Figure S10, File
S1). The new loci showed similar effect sizes and consistent effect
directions for eGFRcrea and eGFRcys, suggesting a relation to
renal function rather than to creatinine metabolism. Placing the
results of these 6 loci in context with our previously identified loci
[8,9] (23 known and 6 novel), 18 were associated with CKD at a
0.05 significance level (odds ratio, OR, from 1.05 to 1.26; P values
from 3.7610216 to 0.01) and 11 with CKD45 (OR from 1.08 to
1.34; P values from 1.161025 to 0.047; Figure S11 and Table S15).
When we examined these 29 renal function loci by age group,
sex, diabetes and hypertension status (Tables S16, S17, S18, and
S19), we observed consistent associations with eGFRcrea for most
loci across all strata, with only two exceptions: UMOD had a
stronger association in older individuals (P value for difference
8.4610213) and in those with hypertension (P value for difference
0.002), and CDK12 was stronger in younger subjects (P value for
difference 0.0008). We tested the interaction between age and
rs11078903 in one of our largest studies, the ARIC study. The
interaction was significant (P value = 0.0047) and direction
consistent with the observed between-strata difference.
Finally, we tested for associations between our 6 new loci and
CKD related traits. The new loci were not associated with urinary
albumin-to-creatinine ratio (UACR) or microalbuminuria [20]
(Tables S20 and S21), with blood pressure from the ICBP
Consortium [21] (Table S22) or with myocardial infarction from
the CARDIoGRAM Consortium [22] (Table S23).
Discussion
We have extended prior knowledge of common genetic variants
for kidney function [8–11,23] by performing genome-wide
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association tests within strata of key CKD risk factors, including
age, sex, diabetes, and hypertension, thus uncovering 6 loci not
previously known to be associated with renal function in
population-based studies (MPPED2, DDX1, CASP9, SLC47A1,
CDK12, INO80). In contrast to our prior genome-wide analysis
[8,9], the majority of the new loci uncovered in the present
analysis have little known prior associations with renal function.
This highlights a continued benefit of the GWAS approach by
using large sample sizes to infer new biology.
Despite our hypothesis that genetic effects are modified by CKD
risk factors, most of the identified variants did not exhibit strong
cross-strata differences. This highlights that many genetic
associations with kidney function may be shared across risk factor
strata. The association of several of these loci with kidney function
in African Americans underscores the generalizability of identified
renal loci across ethnicities. Zebrafish knockdown of mpped2
resulted in abnormal podocyte anatomy as assessed by expression
of glomerular markers, and loss of casp9 led to altered podocyte
and distal tubular marker expression, decreased dextran clearance,
edema, and enhanced susceptibility to gentamicin-induced kidney
damage. These findings demonstrate the potential importance of
these genes with respect to renal function and illustrate that
zebrafish are a useful in vivo model to explore the functional
consequences of GWAS-identified genes.
Despite these strengths, there are some limitations of our study
that warrant discussion. Although we used cystatin C to separate
creatinine metabolism from true filtration loci, SNPs within the
cystatin C gene cluster have been shown to be associated with
cystatin C levels [8], which might result in some degree of
misclassification in absolute levels. While we used standard
definitions of diabetes and hypertension in the setting of
population-based studies, these may differ from those definitions
used in clinical practice. In addition, we were unable to
differentiate the use of anti-hypertension medications from other
clinical indications of these agents or type 1 from type 2 diabetes.
The absence of association between our six newly discovered SNPs
and the urinary albumin to creatinine ratio, blood pressure, and
cardiovascular disease may have resulted from disparate genetic
underpinnings of these traits, the overall small effect sizes, or the
cross-sectional nature of our explorations; and we were unable to
differentiate between these potential issues. Finally, power was
modest to detect between-strata heterogeneity.
With increased sample size and stratified analyses, we have
identified additional loci for kidney function that continue to have
novel biological implications. Our primary findings suggest that
there is substantial generalizability of SNPs associations across
strata of important CKD risk factors, specifically with hyperten-
sion and diabetes.
Figure 1. Genetic association and LD distribution of the MPPED2 gene locus in European and African ancestry populations. Regional
association plots in the CKDGen European ancestry discovery analysis (N = 74,354) (A) and in the CARe African ancestry discovery analysis (N= 8,110)
(B). LD structure: comparison between the HapMap release II – CEU and YRI samples in the region included within +/2100 kb from the target SNP
rs3925584 identified in the CKDGen GWAS. The green circle highlights a stream of high LD connecting the two blocks, indicating the presence of
common haplotypes (C).
doi:10.1371/journal.pgen.1002584.g001
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Materials and Methods
Phenotype definition
Serum creatinine and cystatin C were measured as detailed in
Tables S1 and S2. To account for between-laboratory variation,
serum creatinine was calibrated to the US nationally representa-
tive National Health and Nutrition Examination Study
(NHANES) standards in all discovery and replication studies as
described previously [8,24,25]. GFR based on serum creatinine
(eGFRcrea) was estimated using the four-variable MDRD Study
equation [26]. GFR based on cystatin C (eGFRcys) was estimated
as eGFRcys = 76.76(serum cystatin C)21.19 [27]. eGFRcrea and
eGFRcys values,15 ml/min/1.73 m2 were set to 15, and those
.200 were set to 200 ml/min/1.73 m2. CKD was defined as
eGFRcrea ,60 ml/min/1.73 m2 according to the National
Kidney Foundation guidelines [28]. A more severe CKD
phenotype, CKD45, was defined as eGFRcrea ,45 ml/min/
1.73 m2. Control individuals for both CKD and CKD45 analyses
were defined as those with eGFRcrea .60 ml/min/1.73 m2.
Covariate definitions
In discovery and replication cohorts, diabetes was defined as
fasting glucose $126 mg/dl, pharmacologic treatment for diabe-
tes, or by self-report. Hypertension was defined as systolic blood
pressure $140 mmHg or diastolic blood pressure $90 mmHg or
pharmacologic treatment for hypertension.
Discovery analyses
Genotyping was conducted as specified in Table S4. After
applying quality-control filters to exclude low-quality SNPs or
samples, each study imputed up to ,2.5 million HapMap-II
SNPs, based on the CEU reference samples. Imputed genotypes
were coded as the estimated number of copies of a specified allele
(allelic dosage). Additional, study-specific details can be found in
Table S1.
Primary association analysis
A schematic view of our complete analysis workflow is presented
in Figure S1. Using data from 26 population-based studies of
individuals of European ancestry, we performed GWA analyses of
the following phenotypes: 1) loge(eGFRcrea), loge(eGFRcys),
CKD, and CKD45 overall and 2) loge(eGFRcrea) and CKD
stratified by diabetes status, hypertension status, age group (#/
.65 years), and sex. GWAS of loge(eGFRcrea) and loge(eGFRcys)
were based on linear regression. GWAS of CKD and CKD45
were performed in studies with at least 25 cases (i.e. all 26 studies
for CKD and 11 studies for CKD45) and were based on logistic
regression. Additive genetic effects were assumed and models were
adjusted for age and, where applicable, for sex, study site and
principal components. Imputation uncertainty was accounted for
by including allelic dosages in the model. Where necessary,
relatedness was modeled with appropriate methods (see Table S1
for study-specific details). Before including in the meta-analysis, all
GWA data files underwent to a careful quality control, performed
using the GWAtoolbox package in R (www.eurac.edu/GWA
toolbox.html) [29].
Meta-analyses of study-specific SNP-association results, assum-
ing fixed effects and using inverse-variance weighting, i.e.: the
pooled effect b^pooled is estimated as
PK
i~1 wib^i
.PK
i~1 wi, where b^i
is the effect of the SNP on the outcome in the ith study, K is the
number of studies, and wi~1
.
SE(b^i) is the weight given to the i
th
study. The meta-analyses were performed using METAL [30],
with genomic control correction applied across all imputed SNPs
[31] if the inflation factor l.1 at both the individual study level
and after the meta-analysis. SNPs with minor allele frequency
(MAF),1% were excluded. All SNPs with a meta-analysis P
value#561028 for any trait or any stratum were deemed genome-
wide significant [32].
In the eGFRcrea analyses, after excluding loci that were
previously reported [8,9], we selected for replication all SNPs with
P value,561028 in any trait or stratum that were independent
(defined by pairwise r2,0.2), in the primary association analysis.
This yielded five SNPs in five independent loci. The same criterion
was applied to the CKD analysis, where no SNPs passed the
selection threshold. Given the smaller number of cases with severe
CKD resulting in less statistical power, a different selection
strategy was adopted for the CKD45 analysis: selected for
replication were SNPs with discovery P value#561026,
MAF$5%, and homogeneous effect size across studies
(I2#25%). Four additional SNPs were thereby selected for
replication from the CKD45 analysis.
Direction test to identify SNPs for replication
In addition to identifying SNPs for replication based on the
genome-wide significance threshold from a fixed effect model
meta-analysis, we performed a ‘‘direction test’’ to identify
additional SNPs for which between-study heterogeneity in effect
size might have obscured the overall association that was
nevertheless highly consistent in the direction of allelic effects.
Under the null hypothesis of no association, the a priori probability
that a given effect allele of a SNP has either a positive or negative
association with eGFRcrea is 0.5. Because the meta-analysis
includes independent studies, the number of concordant effect
directions follows a binomial distribution. Therefore, we tested
whether the number of discovery cohorts with the same sign of
association (i.e. direction of effect) was greater than expected by
chance given the binomial distribution and a null expectation of
equal numbers of associations with positive and negative sign. The
test was only applied for eGFRcrea in the overall analysis.
Multiple testing was controlled by applying the same P value
Figure 2. Mpped2 and casp9 knockdowns result in defective kidney development. (A–E) Whole mount in situ hybridization in control
embryos demonstrates normal expression of the global kidney marker pax2a (A: lateral view; B: dorsal view), the glomerular marker nephrin (C), and
the tubular markers slc20a1a (proximal tubule, D), and slc12a3 (distal tubule, E) at 48 hours post fertilization (hpf). (F–J) Mpped2 morpholino (MO)
knockdown embryos develop glomerular gene expression defects (F–H, arrowheads), but tubular marker expression is normal (I, J). (K–O) Casp9 MO
knockdown embryos demonstrate reduced glomerular gene expression (K–M, arrowheads) and shortened distal tubules (O). (P) Quantification of
observed abnormalities per number of embryos reveal significant differences in expression of pax2a and nephrin in response to knockdown of both
mpped2 and casp9 (Fisher’s exact test). (Q–V) Embryos were injected with control, mpped2, or casp9 MO at the one-cell stage and subsequently
injected with 70,000 MW fluorescent rhodamine dextran at 80 hpf. Dextran fluorescence was monitored over the next 48 hours. All dextran-injected
embryos show equal loading into the cardiac sinus venosus at 2 hours post-injection (2 hpi/82 hpf; Q, S, U). Compared to control MO-injected
embryos (R) and mpped2 knockdown embryos (T), knockdown of casp9 resulted in reduced dextran clearance at 48 hpi as shown by increased trunk
fluorescence (V). (W) Casp9 knockdown results in increased susceptibility to edema formation both spontaneously (2dex) (P value = 0.0234, Fisher’s
exact test) and after dextran challenge (+dex) (P value,0.0001). Embryos injected with both MO and dextran did not survive to 6 dpf (N/A). (X) Edema
develops earlier and with higher frequency in casp9 morphants following injection of the nephrotoxin gentamicin.
doi:10.1371/journal.pgen.1002584.g002
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threshold of 561028 as in the overall GWAS. Given that no SNP
met this criterion, we selected for replication one novel SNP with
the lowest P value of 4.061027.
Genome-wide between-strata difference test to identify
SNPs for replication
Based on the results of the stratified GWAS of eGFRcrea and
CKD, for each SNP we tested the hypothesis whether the effect of
a SNP on eGFRcrea or CKD was the same between strata (null
hypothesis), i.e. diabetes versus non-diabetes subjects, hypertensive
versus normotensive, younger versus older, females versus males.
We used a two-sample test defined as Z= (b12b2)/(SE(b1)
2+-
SE(b2)
2)0.5, with b1 and b2 indicating the effect estimates in the two
strata and SE(b1) and SE(b2) their standard errors [33]. For large
samples, the test statistic follows a standard normal distribution.
SNPs were selected for replication if they had a between-stratum
difference P value#561025, an association P value#561025 in
one of the two strata, and MAF$10%. Independent loci were
defined using the same criteria as described above. Eleven further
SNPs, one per locus, were selected for replication from the
between-strata difference test.
Replication analysis
Replication was performed for a total of 21 SNPs including 5
from the overall and stratified eGFRcrea analyses, 1 from the
direction test on eGFRcrea, 4 from the overall CKD45 analysis,
and 11 from the between-strata difference test. Replication studies
used the same phenotype definition, and had available genotypes
from imputed in silico genome-wide SNP data or de novo
genotyping. The same association analyses including the identical
stratifications were performed as in discovery studies. Details can
be found in the Tables S2, S5 and S6. Study-specific replication
results for the selected SNPs were combined using the same meta-
analysis approach and software as in the discovery stage. One-
sided P values were derived with regard to the effect direction
found in the discovery stage. Based on the P value distribution of
all SNPs submitted for replication (the 10 from eGFRcrea and
CKD45 and the 11 from the between strata difference test), we
estimated the False Discovery Rate as a q-value using the
QVALUE [34] package in R. SNPs with q-value,0.05 were
called significantly replicating, thus specifying a list of associations
expected to include not more than 5% false positives.
Finally, study-specific results from both the discovery and
replication stage were combined in a joint inverse-variance
weighted fixed-effect meta-analysis and the two-sided P values
were compared to the genome-wide significance threshold of
561028 to test whether a SNP was genome-wide significant.
Between-study heterogeneity of replicated SNPs was quantified by
the I2 statistic [35].
Replication genotyping
For de novo genotyping in 10,446 samples from KORA F3,
KORA F4, SAPHIR and SAPALDIA, the MassARRAY system
at the Helmholtz Zentrum (Mu¨nchen, Germany) was used, using
Assay Design v3.1.2 and the iPLEX chemistry (Sequenom, San
Diego, USA). Assay design failed for rs1322199 and genotyping
was not performed. Ten percent of the spectra were checked by
two independent, trained persons, and 100% concordance
between investigators was obtained. SNPs with a P value,0.001
when testing for Hardy-Weinberg equilibrium (rs10490130,
rs10068737, rs11078903), SNPs with call rate ,90% (rs500456
in KORA F4 only) or monomorphic SNPs (rs2928148) were
excluded from analyses without attempting further genotyping.
The call rates of rs4149333 and rs752805 were near 0% on the
MassARRAY system. These SNPs were thus genotyped on a
7900HT Fast Real-Time PCR System (Applied Biosystems,
Foster City, USA). Mean call rate across all studies and SNPs
ranged from 96.8% (KORA F4) to 99% (SAPHIR). Duplicate
genotyping was performed in at least 14% of the subjects in each
study with a concordance of 95–100% (median 100%). In the
Ogliastra Genetic Park Replication Study (n = 3000) de novo
genotyping was conducted on a 7900HT Fast Real-Time PCR
System (Applied Biosystems, Foster City, USA), with a mean call
rate of 99.4% and 100% concordance of SNPs genotyped in
duplicate.
Between-strata analyses for candidate SNPs in replication
samples
Twenty-nine SNPs, including the 6 novel loci reported in the
current manuscript along with 23 previously confirmed to be
associated with renal function [9], were tested for differential
effects between the strata. The same Z statistics as described for
discovery (above) was used and the Bonferroni-adjusted signifi-
cance level was set to 0.10/29= 0.003.
SNP-by-age interaction, for the one SNP showing significantly
different effects between strata of age, was tested in the ARIC
study by fitting a linear model on log(eGFRcrea) adjusted for sex,
recruitment site, the first and the seventh genetic principal
components (only these two were associated with the outcome at
P value,0.05). Both the interaction term and the terms for the
main effects of age and the SNP were included in the model.
Power to assess between-strata effect difference
To assess genome-wide between-strata differences, with al-
pha= 561028 and power = 80%, the maximum detectable
difference was 0.025 when comparing nonDM versus DM and
0.015 when comparing nonHTN versus HTN. Similarly, when
testing for between-strata differences the 29 known and new loci
(Bonferroni-corrected alpha= 0.003) in the combined sample
(n =,125,000 in nonDM and n=,13,000 in DM) we had
80% power to detect differences as large as 0.035.
Look-up in African Americans (CARe)
For each of the 6 lead SNPs identified in our European
ancestry samples, we extracted eGFR association statistics from a
genome-wide study in the CARe African ancestry consortium
[12]. We further investigated potential allelic heterogeneity across
ethnicities by examining the 250 kb flanking region surrounding
each lead SNP to determine whether other SNPs with stronger
associations exist in each region. A SNP with the smallest
association P value with MAF.0.03 was considered the top SNP
in the African ancestry sample. We defined statistical significance
of the identified lead SNP in African ancestry individuals based
on a region-specific Bonferroni correction. The number of
independent SNPs was determined based on the variance
inflation factor (VIF) with a recursive calculation within a sliding
window of 50 SNPs and pairwise r2 of 0.2. These analyses were
performed using PLINK.
Analyses of related phenotypes
For each replicating SNP, we obtained association results for
urinary albumin-to-creatinine ratio and microalbuminuria from
our previous genome-wide association analysis [20], and for blood
pressure and myocardial infarction from genome-wide association
analysis from the ICBP [21] and CARDIoGRAM [22] consortia,
respectively.
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eSNP analysis
Significant renal SNPs were searched against a database of
expression SNPs (eSNP) including the following tissues: fresh
lymphocytes [36], fresh leukocytes [37], leukocyte samples in
individuals with Celiac disease [38], lymphoblastoid cell lines
(LCL) derived from asthmatic children [39], HapMap LCL from 3
populations [40], a separate study on HapMap CEU LCL [41],
peripheral blood monocytes [42,43], adipose [44,45] and blood
samples [44], 2 studies on brain cortex [42,46], 3 large studies of
brain regions including prefrontal cortex, visual cortex and
cerebellum (Emilsson, personal communication), liver [45,47],
osteoblasts [48], skin [49] and additional fibroblast, T cell and
LCL samples [50]. The collected eSNP results met criteria for
statistical significance for association with gene transcript levels as
described in the original papers.
A second expression analysis of 81 biopsies from normal kidney
cortex samples was performed as described previously [51,52].
Genotyping was performed using Affymetrix 6.0 Genome-wide chip
and called with GTC Software (Affymetrix). For eQTL analyses,
expression probes (Affymetrix U133set) were linked to SNP probes
with .90% call-rate using RefSeq annotation (Affymetrix build
a30). P values for eQTLs were calculated using linear multivariable
regression in both cohorts and then combined using Fisher’s
combined probability test (see also [52]). Pairwise LD was calculated
using SNAP [53] on the CEU HapMap release 22.
Zebrafish functional experiments
Zebrafish were maintained according to established IACUC
protocols. Briefly, we injected zebrafish embryos with newly
designed (mpped2, ddx1) or previously validated (casp9 [54])
morpholino antisense oligonucleotides (MO, GeneTools, Philo-
math OR) at the one-cell stage at various doses. We fixed embryos
in 4% PFA at the appropriate stages for in situ hybridization
(http://zfin.org/ZFIN/Methods/ThisseProtocol.html). Different
anatomic regions of the kidney were visualized using a panel of
4 established markers: pax2a (global kidney marker) [15], nephrin
(podocyte marker) [16], slc20a1a (proximal tubule) [17], and
slc12a3 (distal tubule marker) [17]. Abnormalities in gene
expression were independently scored by two investigators. We
compared the number of abnormal morphant embryos to control
embryos, injected with a standard control MO designed by
GeneTools, with the Fisher’s exact test, at the Bonferroni-
corrected significance level of 0.0125, i.e.: 0.05/4 markers. We
documented the development of gross edema at 4 and 6 days post-
fertilization in live embryos.
We performed dextran clearance experiments following previ-
ously described protocols [55]. Briefly, 80 hours after MO
injection, we anesthetized embryos in 4 mg/ml Tricaine in
embryo water (1:20 dilution), then positioned embryos on their
back in a 1% agarose injection mold. We injected an equal volume
of tetramethylrhodamine dextran (70,000 MW; Invitrogen) into
the cardiac sinus venosus of each embryo. We then returned the
embryos to fresh embryo water. Using fluorescence microscopy,
we imaged the embryos at 2 hours post-injection (82 hpf) to
demonstrate equal loading, then at 48 hours post-injection (128
hpf) to evaluate dextran clearance.
Embryos were injected with control, mpped2, or casp9 MOs at
the one-cell stage. At 48 hpf, embryos were manually dechor-
ionated, anesthetized in a 1:20 dilution of 4 mg/ml Tricaine in
embryo water, and oriented on a 1% agarose injection mold. As
previously described [56], embryos were injected with equal
volumes of 10 mg/ml gentamicin (Sigma) in the cardiac sinus
venosus, returned to fresh embryo water, and subsequently scored
for edema (prevalence, time of onset) over the next 3 days.
Supporting Information
Figure S1 Flowchart of the project.
(TIF)
Figure S2 Genome-wide 2log10 P values plot from stage 1
discovery meta-analysis. Plots show the discovery analysis of
eGFRcrea in the overall group, with known loci [8,9] highlighted
in orange and novel loci highlighted in blue (A), and in strata of the
main CKD risk factors (B, C, D, and E), with complementary
groups being contrasted each other. The dotted line indicates the
genome-wide significance threshold at P value = 561028. The
unmarked locus is RNASEH2C on chromosome 11, colored in
gray despite genome-wide significance. The P value for the current
stage 1 discovery for rs4014195 was 2.761029. This locus
previously did not replicate [9]; when we additionally considered
our prior non-overlapping in silico and de novo replication data,
the current stage 2 P value was 0.8832, yielding a combined stage
1+stage 2 P value of 2.661027. Therefore, we did not submit this
SNP for further replication.
(PDF)
Figure S3 Quantile-quantile plots of observed versus expected
2log10 P values from the discovery analysis of eGFRcrea overall
(A) and by strata of the main CKD risk factors (B). The orange line
and its 95% confidence interval (shaded area) represent the null
hypothesis of no association. In panel (A), results are compared
when considering all SNPs (black dots) and when removing SNPs
from loci that were already reported in previous GWAS [8,9]
(orange dots). The meta-analysis inflation factor l is reported
along with the discovery sample size. Individual-study minimum,
maximum and median ls are also reported for comparison.
Genomic-control correction was applied twice: on individual study
results, before the meta-analysis, and on the meta-analysis results.
(PDF)
Figure S4 Regional association plots for the six new loci in the
European ancestry discovery samples: (A) MPPED2; (B) DDX1; (C)
SLC47A1; (D) CASP9; (E) CDK12; (F) INO80. 2log10 P values are
plotted versus genomic position(build 36). The lead SNP in each
region is labeled. Other SNPs in each region are color-coded
based on their LD to the lead SNP(LD based on the HapMap
CEU, see color legend). Gene annotations are based on UCSC
Genome Browser(RefSeq Genes, build 36) and arrows indicate
direction of transcription. Graphs were generated using the stand-
alone version of LocusZoom [57], version 1.1.
(PDF)
Figure S5 Forest plots of the six novel loci in the discovery
phase.
(TIF)
Figure S6 Results from discovery meta-analysis of eGFRcrea for
the six new loci: overall sample and all strata are considered.
Reported is the effect size on log(eGFRcrea) and its 95%
confidence interval. The stratum where the SNP was discovered
is marked with a triangle for discovery based on meta-analysis P
value or with a circle for discovery based on direction test.
(TIF)
Figure S7 Regional association plots for the six new loci in the
African ancestry CARe samples: (A) MPPED2; (B) DDX1; (C)
SLC47A1; (D) CASP9; (E) CDK12; (F) INO80. 2log10 P values are
plotted versus genomic position (build 36). The lead SNP in each
region is labeled and identified by a blue arrow and blue P value.
The SNP with the smallest P value in the region is indicated by a
red arrow. Other SNPs in each region are color-coded based on
their LD to the lead SNP (based on the HapMap YRI, see color
GWAS Reveals New Loci for Kidney Function
PLoS Genetics | www.plosgenetics.org 12 March 2012 | Volume 8 | Issue 3 | e1002584
legend). Gene annotation is based on UCSC Genome Browser
(RefSeq Genes, build 36) and arrows indicate direction of
transcription. Graphs were generated using the stand-alone
version of LocusZoom [57], version 1.1.
(PDF)
Figure S8 Ddx1 knockdown does not affect kidney gene
expression. (A–E) Uninjected control embryos show normal
kidney development as demonstrated by in situ hybridization for
the renal markers pax2a (A, B), nephrin (C), slc20a1a (D) and slc12a3
(E). (F–J) Ddx1 morpholino(MO)-injected embryos do not show
significant changes in renal marker expression. (K) Number of
observed abnormalities per number of embryos examined at
400 uM MO injection for renal gene expression analysis.
(TIF)
Figure S9 Casp9 and mpped2 knockdown embryos are more
susceptible to gentamicin-induced kidney injury. Compared to
control embryos (A), casp9 and mpped2 knockdown embryos
develop edema at 103 hpf (C, E), suggestive of a renal defect. When
injected with gentamicin, a nephrotoxin that reproducibly induces
edema in control embryos (B), mpped2 and casp9 knockdown
embryos develop edema earlier, more frequently, and in a more
severe fashion (D, F). Whereas control embryos primarily develop
cardiac edema, mpped2 and casp9 knockdown embryos display
cardiac (arrowhead), ocular (black arrow), and visceral (white arrow)
edema, demonstrating that mpped2 and casp9 knockdown
predisposes embryos to kidney injury. (G) Quantification of edema
prevalence in control, mpped2, and casp9 knockdown embryos 2,
22, and 55 hours post-injection (hpi) of gentamicin. These numbers
are presented graphically in Figure 2X.
(TIF)
Figure S10 Comparison of the effect size on eGFRcrea and on
eGFRcys for the lead SNPs of known and new loci. Results are
based on the largest sample size available for each locus, i.e. the
combined discovery and replication sample for the novel loci
(N= 130,600), the discovery sample only for the known loci
(N= 74,354). Sign of effect estimates has been changed to reflect
the effects of the eGFRcrea lowering alleles. Original beta
coefficients and their standard errors for the two traits can be
downloaded from the File S1.
(TIF)
Figure S11 Odds ratios (ORs) and 95% confidence intervals of
CKD and CKD45 for the lead SNPs of all known and new loci,
sorted by decreasing OR of CKD.
(TIF)
File S1 Effect size on eGFRcrea and on eGFRcys for the lead
SNPs of known and new loci.
(XLSX)
Table S1 Study-specific methods and full acknowledgments—
discovery studies.
(DOC)
Table S2 Study-specific methods and full acknowledgments—
replication studies and functional follow-up studies.
(DOC)
Table S3 Characteristics of stage 1 discovery studies.
(DOC)
Table S4 Study-specific genotyping information for stage 1
discovery studies.
(DOC)
Table S5 Characteristics of stage 2 replication studies.
(DOC)
Table S6 Study-specific genotyping information for stage 2 in
silico replication studies.
(DOC)
Table S7 Top four SNPs from the CKD45 analysis.
(DOC)
Table S8 Loci identified by the test for differential effects
between strata in the GWAS. Results are sorted by trait, group
and chromosome. For each SNP, the P value of the test for
difference between strata is reported.
(DOC)
Table S9 Imputation quality of replicated SNPs in all discovery
and replication studies: median MACH-Rsq and interquartile
range (IQR) are reported.
(DOC)
Table S10 Effects of novel and known loci on log(eGFRcrea) in
the overall population.
(DOC)
Table S11 Genes nearest to loci associated with renal traits.
(DOC)
Table S12 Imputation Quality (MACH-Rsq) for the best SNPs
in the African ancestry samples of the CARe consortium (1.00
refers to genotyped data).
(DOC)
Table S13 Baseline characteristics of the kidney biopsies for the
eQTL analysis.
(DOC)
Table S14 Analysis of the new loci for eQTL status in meta-
analysis of two cohorts of kidney biopsies.
(DOC)
Table S15 Association of novel and known loci with CKD and
CKD45: Odds Ratios (OR), 95% confidence intervals (95%CI)
and P values.
(DOC)
Table S16 Association between novel and known loci and
log(eGFRcrea) in individuals without and with diabetes and test
for difference between strata.
(DOC)
Table S17 Association between novel and known loci and
log(eGFRcrea) in individuals without and with hypertension and
test for difference between strata.
(DOC)
Table S18 Association between novel and known loci and
log(eGFRcrea) in individuals younger and older than 65 years and
test for difference between strata.
(DOC)
Table S19 Association between novel and known loci and
log(eGFRcrea) in females and in males and test for difference
between strata.
(DOC)
Table S20 Effects of novel loci on the logarithm of urinary
albumin-to-creatinine ratio (log(UACR)) in the overall sample and
by diabetes and hypertension status.
(DOC)
Table S21 Effects (log odds ratios) of novel loci on microalbu-
minuria (MA) in the overall sample and by diabetes and
hypertension status.
(DOC)
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Table S22 Association of novel loci with diastolic and systolic
blood pressure in the ICBP consortium.
(DOC)
Table S23 Association of novel loci with myocardial infarction
in the CARDIoGRAM consortium.
(DOC)
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